Boosting functional avidity of cd8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell Myd88 expression but not the inflammatory milieu

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5356-5368

  Hu, Zhidong ^a   Wang, Jing ^a   Wan, Yanmin ^a   Zhu, Lingyan ^a   Ren, Xiaonan ^a   Qiu, Sugan ^a   Ren, Yanqin ^a   Yuan, Songhua ^a   Ding, Xiangqing ^a   Chen, Jian ^a   Qiu, Chenli ^a   Sun, Jun ^a   Zhang, Xiaoyan ^a,b   Xiang, Jim ^c   Qiu, Chao ^a   Xu, Jianqing ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b State Key Laboratory for Infectious Disease Prevention and Control   (China)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MYELOID DIFFERENTIATION FACTOR 88; POXVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; VACCINIA VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VACCINATION; VACCINIA VIRUS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; SMALLPOX VACCINE; VACCINIA VIRUS;

EID: 84899056431     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03664-13     Document Type: Article

References (45)

1. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205:63-77. http://dx.doi.org/10.1084/jem.20071331.
2. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G. 2008. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490. http://dx.doi.org/10.1086/592507.
3. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML. 2010. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east Africans (RV 172). J. Infect. Dis. 201:600-607. http://dx.doi.org/10.1086/650299.
4. Ranasinghe C, Ramshaw IA. 2009. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev. Vaccines 8:1171-1181. http://dx.doi.org/10.1586/erv.09.86.
5. Paris RM, Kim JH, Robb ML, Michael NL. 2010. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev. Vaccines 9:1055-1069. http://dx.doi.org/10.1586/erv.10.106.
6. Lousberg EL, Diener KR, Brown MP, Hayball JD. 2011. Innate immune recognition of poxviral vaccine vectors. Expert Rev. Vaccines 10:1435- 1449. http://dx.doi.org/10.1586/erv.11.121.
7. Pantaleo G, Esteban M, Jacobs B, Tartaglia J. 2010. Poxvirus vectorbased HIV vaccines. Curr. Opin. HIV AIDS 5:391-396. http://dx.doi.org/10.1097/COH.0b013e32833d1e87.
8. Appay V, Douek DC, Price DA. 2008. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14:623-628. http://dx.doi.org/10.1038/nm.f.1774.
9. Alexander-Miller MA. 2005. High-avidity CD8+ cells: optimal soldiers in the war against viruses and tumors. Immunol. Res. 31:13-24. http://dx.doi.org/10.1385/IR:31:1:13.
10. Vigano S, Utzschneider DT, Perreau M, Pantaleo G, Zehn D, Harari A. 2012. Functional avidity: a measure to predict the efficacy of effector T cells? Clin. Dev. Immunol. 2012:153863. http://dx.doi.org/10.1155/2012/153863.
11. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, Larsen M, Pancino G, Douek DC, Autran B, Saez-Cirion A, Appay V. 2009. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113:6351-6360. http://dx.doi.org/10.1182/blood-2009-02-206557.
12. Derby M, Alexander-Miller M, Tse R, Berzofsky J. 2001. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166:1690-1697. http://www.jimmunol.org/content/166/3/1690.long.
13. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, Ruiz-Riol M, Berger CT, Herrero MJ, Palou E, Plana M, Rolland M, Khatri A, Heckerman D, Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber BK, Pavlakis GN, Mullins JI, Brander C. 2012. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 7:e29717. http://dx.doi.org/10.1371/journal.pone.0029717.
14. Appay V, Iglesias MC. 2011. Antigen sensitivity and T-cell receptor avidity as critical determinants of HIV control. Curr. Opin. HIV AIDS 6:157- 162. http://dx.doi.org/10.1097/COH.0b013e3283453dfd.
15. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V. 2007. Superior control of HIV-1 replication by CD+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204:2473- 2485. http://dx.doi.org/10.1084/jem.20070784.
16. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. 2002. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int. Immunol. 14:31-37. http://dx.doi.org/10.1093/intimm/14.1.31.
17. Ranasinghe C, Turner SJ, McArthur C, Sutherland DB, Kim JH, Doherty PC, Ramshaw IA. 2007. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J. Immunol. 178:2370-2379. http://www.jimmunol.org/content/178/4/2370.long.
18. Richer MJ, Nolz JC, Harty JT. 2013. Pathogen-specific inflammatory milieu tune the antigen sensitivity of CD8(+) T cells by enhancing T cell receptor signaling. Immunity 38:140-152. http://dx.doi.org/10.1016/j.immuni.2012.09.017.
19. von Essen MR, Kongsbak M, Geisler C. 2012. Mechanisms behind functional avidity maturation in T cells. Clin. Dev. Immunol. 2012: 163453. http://dx.doi.org/10.1155/2012/163453.
20. Zhu J, Martinez J, Huang X, Yang Y. 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:619-625. http://dx.doi.org/10.1182/blood-2006-06-027136.
21. Lousberg EL, Diener KR, Fraser CK, Phipps S, Foster PS, Chen W, Uematsu S, Akira S, Robertson SA, Brown MP, Hayball JD. 2011. Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of Toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition. J. Virol. 85:3385-3396.http://dx.doi.org/10.1128/JVI.02000-10.
22. Elena GC, Perdiguero B, Garcia-Arriaza J, Esteban M. 2012. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum. Vaccin. Immunother. 8:1192-1207. http://dx.doi.org/10.4161/hv.20778.
23. Wan Y, Wu L, Liu L, Xu J, Liu Y, Liu Y, Shao Y. 2007. Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Vaccine 25:4949-4959. http://dx.doi.org/10.1016/j.vaccine.2007.01.118.
24. Li HS, Liu Y, Li DF, Zhang RR, Tang HL, Zhang YW, Huang W, Liu Y, Peng H, Xu JQ, Hong KX, Shao YM. 2007. Enhancement of DNA vaccine-induced immune responses by a 72-bp element from SV40 enhancer. Chin Med. J. 120:496-502. http://www.cmj.org/ch/reader/view_abstract.aspx?volume=120&issue=6&start_page=496.
25. Liu Y, Li F, Liu Y, Hong K, Meng X, Chen J, Zhang Z, Huo Z, Sun M, Self SG, Shao Y. 2011. HIV fragment gag vaccine induces broader T cell response in mice. Vaccine 29:2582-2589. http://dx.doi.org/10.1016/j.vaccine.2011.01.049.
26. van Stipdonk MJ, Hardenberg G, Bijker MS, Lemmens EE, Droin NM, Green DR, Schoenberger SP. 2003. Dynamic programming of CD8+ T lymphocyte responses. Nat. Immunol. 4:361-365. http://dx.doi.org/10.1038/ni912.
27. Reddy J, Bettelli E, Nicholson L, Waldner H, Jang MH, Wucherpfennig KW, Kuchroo VK. 2003. Detection of autoreactive myelin proteolipid protein 139-151-specific T cells by using MHC II (IAs) tetramers. J. Immunol. 170:870-877. http://www.jimmunol.org/content/170/2/870.long.
28. Sharma SK, Alexander-Miller MA. 2011. Increased sensitivity to antigen in high avidity CD8(+) T cells results from augmented membrane proximal T-cell receptor signal transduction. Immunology 133:307-317. http://dx.doi.org/10.1111/j.1365-2567.2011.03440.x.
29. Busch DH, Pamer EG. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189:701-710. http://dx.doi.org/10.1084/jem.189.4.701.
30. Davis MM. 2002. A new trigger for T cells. Cell 110:285-287. http://dx.doi.org/10.1016/S0092-8674(02)00865-6.
31. Luik RM, Lewis RS. 2007. New insights into the molecular mechanisms of store-operated Ca2+ signaling in T cells. Trends Mol. Med. 13:103-107. http://dx.doi.org/10.1016/j.molmed.2007.01.004.
32. Amoah S, Yammani RD, Grayson JM, Alexander-Miller MA. 2012. Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection. J. Immunol. 189:638- 645. http://dx.doi.org/10.4049/jimmunol.1102579.
33. Huang Y, Qiu C, Liu LX, Feng YM, Zhu T, Xu JQ. 2009. A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/ HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine. Chin Med. J. 122:1655-1659. http://www.cmj.org/ch/reader/view_abstract.aspx?volume=122&issue=14&start_page=1655.
34. Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, Schendel DJ. 2012. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J. Immunol. 189:598-605. http://dx.doi.org/10.4049/jimmunol.1102165.
35. Zhao Y, De Trez C, Flynn R, Ware CF, Croft M, Salek-Ardakani S. 2009. The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J. Immunol. 182:6278-6286. http://dx.doi.org/10.4049/jimmunol.0803682.
36. Valkenburg SA, Gras S, Guillonneau C, La Gruta NL, Thomas PG, Purcell AW, Rossjohn J, Doherty PC, Turner SJ, Kedzierska K. 2010. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS Pathog. 6:e1001039. http://dx.doi.org/10.1371/journal.ppat.1001039.
37. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL. 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14:1390-1395. http://dx.doi.org/10.1038/nm.1779.
38. Quigley M, Martinez J, Huang X, Yang Y. 2009. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 113:2256-2264. http://dx.doi.org/10.1182/blood-2008-03-148809.
39. Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila E. 2010. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood 116: 3494-3504. http://dx.doi.org/10.1182/blood-2010-02-268169.
40. Tabiasco J, Devevre E, Rufer N, Salaun B, Cerottini JC, Speiser D, Romero P. 2006. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J. Immunol. 177:8708-8713. http://www.jimmunol.org/content/177/12/8708.full.
41. Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang CK, Dicks MD, Wang D, Longley RJ, Wyllie DH, Hill AV. 2012. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol. Ther. 20:1633-1647. http://dx.doi.org/10.1038/mt.2012.25.
42. Park SH, Yang SH, Lee CG, Youn JW, Chang J, Sung YC. 2003. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 21:4555-4564. http://dx.doi.org/10.1016/S0264-410X(03)00499-7.
43. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. 1992. Long-term persistence of plasmidDNAand foreign gene expression in mouse muscle. Hum. Mol. Genet. 1:363-369. http://dx.doi.org/10.1093/hmg/1.6.363.
44. Larsson M, Fonteneau JF, Somersan S, Sanders C, Bickham K, Thomas EK, Mahnke K, Bhardwaj N. 2001. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur. J. Immunol. 31:3432-3442.http://dx.doi.org/10.1002/1521-4141(200112)31:123432::AID-IMMU3432>3.0.CO;2-R.
45. Fischer MA, Norbury CC. 2007. Initiation of primary anti-vaccinia virus immunity in vivo. Immunol. Res. 37:113-133. http://dx.doi.org/10.1007/BF02685894.